Allarity Therapeutics (ALLR) News Today $0.94 +0.14 (+17.93%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.94 0.00 (-0.11%) As of 04/17/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Allarity Therapeutics Restructures Board of DirectorsApril 16 at 5:16 PM | tipranks.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. ...April 14, 2025 | gurufocus.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmApril 14, 2025 | prnewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateApril 2, 2025 | finanznachrichten.deAllarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | markets.businessinsider.comAllarity Therapeutics probes potential stock manipulationMarch 26, 2025 | uk.investing.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 25, 2025 | prnewswire.comAllarity launches effort to combat potential illegal naked short sellingMarch 24, 2025 | markets.businessinsider.comAllarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its SharesMarch 24, 2025 | markets.businessinsider.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 19, 2025 | prnewswire.comAllarity announces presentation from Phase 2 trial with stenoparib monotherapyMarch 17, 2025 | markets.businessinsider.comALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 14, 2025 | prnewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange CommissionMarch 14, 2025 | finanznachrichten.deAllarity sees cash runway into 2026March 14, 2025 | markets.businessinsider.comAllarity announces final settlement with SEC including $2.5M civil penaltyMarch 13, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange CommissionMarch 13, 2025 | globenewswire.comAllarity announes Phase 2 trial of stenoparib with temozolomideMarch 6, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans AdministrationMarch 6, 2025 | globenewswire.comAllarity announces board authorization of $5M share repurchase programMarch 3, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase ProgramMarch 3, 2025 | finance.yahoo.comAllarity announces dismissal of securities class action lawsuitFebruary 26, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Dismissal of Securities Class Action LawsuitFebruary 26, 2025 | globenewswire.comAllarity to begin enrollments for Phase 2 protocol to advance stenoparibFebruary 24, 2025 | markets.businessinsider.comAllarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer PatientsFebruary 24, 2025 | globenewswire.comAllarity Therapeutics advances ovarian cancer drug trialFebruary 6, 2025 | msn.comAllarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian CancerFebruary 6, 2025 | globenewswire.comAllarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SECJanuary 30, 2025 | globenewswire.comAllarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff MotionDecember 6, 2024 | globenewswire.comAllarity reports progress in Phase 2 stenoparib trialNovember 18, 2024 | markets.businessinsider.comAllarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate AdvancementsNovember 18, 2024 | globenewswire.comAllarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational HighlightsNovember 14, 2024 | markets.businessinsider.comALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmNovember 12, 2024 | businesswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity TherapeuticsNovember 12, 2024 | tmcnet.comALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmNovember 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLRNovember 10, 2024 | prnewswire.comALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLRNovember 9, 2024 | globenewswire.comALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their RightsNovember 8, 2024 | businesswire.comALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!November 8, 2024 | globenewswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)November 8, 2024 | businesswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity TherapeuticsNovember 8, 2024 | prnewswire.comALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud LawsuitNovember 7, 2024 | prnewswire.comALLR FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLRNovember 7, 2024 | globenewswire.comALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud LawsuitNovember 7, 2024 | prnewswire.comALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the FirmNovember 5, 2024 | globenewswire.comALLR FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLRNovember 5, 2024 | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)November 4, 2024 | globenewswire.comALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmNovember 4, 2024 | prnewswire.comALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!November 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLRNovember 2, 2024 | prnewswire.comALLR DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLRNovember 2, 2024 | globenewswire.com Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLR Media Mentions By Week ALLR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLR News Sentiment▼0.040.53▲Average Medical News Sentiment ALLR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLR Articles This Week▼44▲ALLR Articles Average Week Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Calidi Biotherapeutics News Orgenesis News Sol-Gel Technologies News ABVC BioPharma News TherapeuticsMD News Marker Therapeutics News iBio News Incannex Healthcare News Moleculin Biotech News Bright Green News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLR) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLR Stock Free ALLR Stock Alerts